[Articles] Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial

Related Posts

• [Correspondence] Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm – Authors' reply

  We appreciate the Correspondences from Thorvardur R Halfdanarson and colleagues, Giuseppe Lamberti and colleagues, and…

• [Articles] Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

  Our study indicates that AI applied on hepatocellular carcinoma digital slides is able to serve…

• [Articles] Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

  RAGNAR results show clinical benefit for erdafitinib in the tumour-agnostic setting in patients with advanced…